NCT06858735View on ClinicalTrials.gov

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

November 19, 2028

Study Completion Date

November 19, 2030

Conditions
Advanced Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Durvalumab

Given by IV

DRUG

Gemcitabine

Given by IV

DRUG

Cisplatin

Given by IV

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Varian Medical Systems, Inc.

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER